Magnetic targeting and ultrasonic release of the inhibitors of the mice colon mechanotransductive tumorigenic pathways in vivo2018 - I. Farge (team Farge, UMR168)
Colorectal cancer is the 3rd most common cancer and the 4th leading cause of cancer-related death worldwide. Each year, are declared 1.4 millions new cases of CRC and up to 2.4 millions in 2035 (WHO, 2012). Although the current treatments demonstrate certain efficiency, recurrence still occurs in 50% patients. The still unknown underlying mechanisms that conduct to this recurrence need to be elucidated, which could allow the appropriate therapy hoping to eradicate the relapse and the resulting death.
The team has found in mice a new parameter potentially involved in colon tumour progression : the mechanical strains associated to tumour growth pressure. The latter were indeed found as an activator of tumorigenic pathways of hyperproliferation and of tumorigenesis in the healthy epithelial cells compressed by neighbouring growing tumours, in the predisposition genetic context for 85% of human colorectal cancer.
Commercialized pharmacological inhibitors of such mechanosensitive tumorigenic pathway were already successfully tested in the team to block mechanical induction of tumorigenesis stimulation. The project consists in establishing in mice a new optimized and patentable treatment of colorectal cancer, based on specific magnetic targeting and ultrasonic progressive release of the colon tumour mechanical induction inhibitor.